PDCD1 and hepatocellular carcinoma: For example, the additive effect of hepatic injury was observed when PD1/PDL1 inhibitors were combined with RT and anti-angiogenesis agents in patients with HCC.[32] Similarly, the choice of PD1/PDL1 inhibitors, tumor histology, mutational burden, and RT are associated with distinct AEs.[33]